$PLPL Baltimore, Maryland / January 14, 2014 / Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes that throughout 2013, management and the scientific team at Plandaí Biotechnology, Inc. (OTCQB –PLPL) succeeded in making meaningful progress on its flagship Phytofare™ Catechin Complex and the high degree of bioavailability of the product’s nutrients to treat a host of illnesses and chronic conditions. As we have now entered 2014, the Company’s medical marijuana initiatives, announced in the fourth quarter of 2013, may take center stage now that the nation has overwhelmingly changed its stance toward broad and widespread cannabis acceptance.